Evidence map›Paper›PMID 35300351›Full record

ArticleFrontiers in neurology2021

Quantification of Brain β-Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study.

Michela Garon, Luca Weis, Eleonora Fiorenzato, Francesca Pistonesi, Annachiara Cagnin, Alessandra Bertoldo, Mariagiulia Anglani, Diego Cecchin, Angelo Antonini, Roberta Biundo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Sequential scans ofJapanese journal of radiology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Michela GaronParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Luca WeisParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Eleonora FiorenzatoDepartment of General Psychology, University of Padua, Padua, Italy.
Francesca PistonesiParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Annachiara CagninDepartment of Neuroscience, University of Padua, Padua, Italy.
Alessandra BertoldoPadova Neuroscience Center, University of Padua, Padua, Italy.
Mariagiulia AnglaniNeuroradiology Unit, Padua University Hospital, Padua, Italy.
Diego CecchinPadova Neuroscience Center, University of Padua, Padua, Italy.
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Roberta BiundoDepartment of General Psychology, University of Padua, Padua, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with faster cognitive decline and conversion to dementia. There is uncertainty about the role of β-amyloid (Aβ) co-pathology and its contribution to the variability in PD-MCI profile and cognitive progression. Objective: To study how presence of Aβ affects clinical and cognitive manifestations as well as regional brain volumes in PD-MCI. Methods: Twenty-five PD-MCI patients underwent simultaneous PET/3T-MRI with [ Results: There were 8 Aβ+ and 17 Aβ- PD-MCI. They did not differ for age, disease duration, clinical, motor, behavioral, and global cognition scores. PD-MCI-Aβ+ showed worse performance in the overall executive domain ( Conclusions: Presence of cerebral Aβ worsens executive functions, but not motor and global cognitive abilities in PD-MCI, and it is not associated with middle-temporal cortex atrophy. These findings, together with the observation of significant proportion of PD-MCI-Aβ-, suggest that Aβ may not be the main pathogenetic determinant of cognitive deterioration in PD-MCI, but it would rather aggravate deficits in domains vulnerable to Parkinson primary pathology.

Indexed as

amyloid-βatrophycognitiondementiaexecutive functionsmild cognitive impairmentParkinson's diseasePET

Identifiers

PMID35300351
PMCPMC8921107
OpenAlexW4214689898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.